Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238

International Journal of Cancer

Volumn 82, Issue 4, 1999, Pages 592-598

  Kahán, Zsuzsanna ^a,b,c   Nagy, Attila ^a,b   Schally, Andrew V ^a,b   Hebert, Francine ^a   Sun, Baodong ^a,b   Groot, Kate ^a   Halmos, Gábor ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLINODOXORUBICIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN DERIVATIVE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CACHEXIA; CANCER INHIBITION; CANCER REGRESSION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MORTALITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL DIVISION; DOXORUBICIN; FEMALE; GROWTH HORMONE; HUMANS; IMMUNOTOXINS; LUTEINIZING HORMONE; MICE; MICE, NUDE; PYRROLES; RECEPTORS, SOMATOSTATIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032816763     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990812)82:4<592::AID-IJC20>3.0.CO;2-0     Document Type: Article

References (25)

1. BUSCAIL, L., DELESQUE, N., ESTÈVE, J.P., SAINT-LAURENT, N., PRATS, H., CLERC, P., ROBBERECHT, P., BELL, G., LIEBOW, C., SCHALLY, A.V., VAYSSE, N. and SUSINI, C., Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. nat. Acad. Sci. (Wash.), 91, 2315-2319 (1994).
2. CLARKE, R., Human breast cancer cell line xenografts as models of breast cancer - the immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res. Treat., 39, 69-86 (1996).
3. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res., 58, 437-441 (1998).
4. EVANS, A.A., CROOK, T., LAWS, S.A.M., GOUGH, A.C., ROYLE, G.T. and PRIMROSE, J.N., Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Brit. J. Cancer, 75, 798-803 (1997).
5. HOFLAND, L.J., VAN KOETSVELD, P.M., WAAIJERS, M. and LAMBERTS, S.W.J., Internalization of isotope-coupled somatostatin analogues. Digestion, 57 (Suppl. 1), 2-6 (1996).
6. KOPPÁN, M., NAGY, A., SCHALLY, A.V., ARENCIBIA, J.M., PLONOWSKI, A. and HALMOS, G., Targeted cytotoxic analog of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res., 58, 4132-4137 (1998).
7. 3]octreotide: the Rotterdam experience with more than 1000 patients. Europ. J. nucl. Med., 20, 716-730 (1993).
8. MIYAZAKI, M., NAGY, A., SCHALLY, A.V., LAMHARZI, N., HALMOS, G., SZEPESHÁZI, K., GROOT, K. and ARMATIS, P., Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J. nat. Cancer Inst., 89, 1803-1809 (1997).
9. MOREL, G., PELLETIER, G. and HEISLER, S., Internalization and subcellular distribution of radiolabeled somatostatin-28 in mouse anterior pituitary tumor cells. Endocrinology, 119, 1972-1979 (1986).
10. NAGY, A., ARMATIS, P. and SCHALLY, A.V., High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc nat. Acad. Sci. (Wash.), 93, 2464-2469 (1996).
11. NAGY, A., SCHALLY, A.V., HALMOS, G., ARMATIS, P., CAI, R.-Z., CSERNUS, V., KOVÁCS, M., KOPPÁN, M., SZEPESHÁZI, K. and KAHÁN, Z., Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. nat. Acad. Sci. (Wash.), 95, 1794-1799 (1998).
12. POLLAK, M.N. and SCHALLY, A.V., Mechanisms of antineoplastic action of somatostatin analogs. Proc. Soc. exp. Biol. Med., 217, 143-152 (1998).
13. PRÉVOST, G., PROVOST, P., SALLÉ, V., LANSON, M. and THOMAS, F., A cross-linking assay allows the detection of receptors for the somatostatin analogue Lanreotide in human breast tumours. Europ. J. Cancer, 29, 1589-1592 (1993).
14. REUBI, J.C., SCHAER, J.-C., LAISSUE, J.A. and WASER, B., Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism, 45, 39-41 (1996).
15. REUBI, J.C., SCHAER, J.C., WASER, B. and MENGOD, G., Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res., 54, 3455-3459 (1994).
16. REUBI, J.C., WASER, B., FOEKENS, J.A., KLIJN, J.G.M., LAMBERTS, S.W.J. and LAISSUE, J., Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relation to EGF receptors. Int. J. Cancer, 46, 416-420 (1990).
17. RIPAMONTI, M., PESSONI, G., PESENTI, E., PASTORI, M., FRAO, M., BARGIOTTI, A., SUARATO, A., SPREAFICO, F. and GRANDI, M., In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Brit. J. Cancer, 65, 703-707 (1992).
18. SCHAER, J.-C., WASER, B., MENGOD, G. and REUBI, J.C., Somatostatin receptor subtypes sst1, sst2, sst3, and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int. J. Cancer, 70, 530-537 (1997).
19. 3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin. Cancer Res., 4, 2047-2052 (1998).
20. SRKALOVIC, G., CAI, R.-Z. and SCHALLY, A.V., Evaluation of receptors for somatostatin in various tumors using different analogs. J. clin. Endocrinol. Metab., 70, 661-669 (1990).
21. SZEPESHÁZI, K., MILOVANOVIC, S., LAPIS, K., GROOT, K. and SCHALLY, A.V., Growth inhibition of estrogen-independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res. Treat., 21, 181-192 (1992).
22. TAYLOR, J.E., THEVENIAU, M.A., BASHIRZADEH, R., REISINE, T. and EDEN, P.A., Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides, 15, 1229-1236 (1994).
23. VISSER-WISSELAAR, H.A., HOFLAND, L.J., VAN UFFELEN, C.J.C., VAN KOETSVELD, P.M. and LAMBERTS, S.W.J., Somatostatin receptor manipulation. Digestion, 57 (Suppl. 1), 7-10 (1996).
24. WECKBECKER, G., RAULF, F., STOLZ, B. and BRUNS, C., Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther., 60, 245-264 (1993).
25. WISEMAN, G.A. and KVOLS, L.K., Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. nucl. Med., 25, 272-278 (1995).